The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Patients' expression of CEACAM5 might hold the key to activity after all.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.